全文获取类型
收费全文 | 945篇 |
免费 | 53篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 14篇 |
妇产科学 | 9篇 |
基础医学 | 85篇 |
口腔科学 | 7篇 |
临床医学 | 93篇 |
内科学 | 158篇 |
皮肤病学 | 5篇 |
神经病学 | 22篇 |
特种医学 | 95篇 |
外科学 | 130篇 |
综合类 | 29篇 |
预防医学 | 91篇 |
眼科学 | 17篇 |
药学 | 87篇 |
中国医学 | 5篇 |
肿瘤学 | 155篇 |
出版年
2023年 | 3篇 |
2022年 | 8篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 16篇 |
2018年 | 15篇 |
2017年 | 12篇 |
2016年 | 16篇 |
2015年 | 15篇 |
2014年 | 29篇 |
2013年 | 53篇 |
2012年 | 55篇 |
2011年 | 65篇 |
2010年 | 42篇 |
2009年 | 40篇 |
2008年 | 66篇 |
2007年 | 55篇 |
2006年 | 56篇 |
2005年 | 41篇 |
2004年 | 40篇 |
2003年 | 40篇 |
2002年 | 30篇 |
2001年 | 13篇 |
2000年 | 11篇 |
1999年 | 17篇 |
1998年 | 18篇 |
1997年 | 18篇 |
1996年 | 21篇 |
1995年 | 17篇 |
1994年 | 10篇 |
1993年 | 13篇 |
1992年 | 10篇 |
1991年 | 7篇 |
1990年 | 8篇 |
1989年 | 14篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 11篇 |
1985年 | 13篇 |
1984年 | 8篇 |
1983年 | 7篇 |
1982年 | 10篇 |
1981年 | 7篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1968年 | 1篇 |
排序方式: 共有1002条查询结果,搜索用时 15 毫秒
91.
Byrd JC Lin TS Dalton JT Wu D Phelps MA Fischer B Moran M Blum KA Rovin B Brooker-McEldowney M Broering S Schaaf LJ Johnson AJ Lucas DM Heerema NA Lozanski G Young DC Suarez JR Colevas AD Grever MR 《Blood》2007,109(2):399-404
Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine serum contributed to an effective pharmacokinetic-derived schedule of administration of this agent. On the basis of pharmacokinetic modeling using our in vitro results and data from a previous trial, we initiated a phase 1 study using a 30-minute loading dose followed by 4 hours of infusion administered weekly for 4 of 6 weeks in patients with refractory CLL. A group of 42 patients were enrolled on 3 cohorts (cohort 1, 30 mg/m2 loading dose followed by 30 mg/m2 4-hour infusion; cohort 2, 40 mg/m2 loading dose followed by 40 mg/m2 4-hour infusion; and cohort 3, cohort 1 dose for treatments 1 to 4, then a 30 mg/m2 loading dose followed by a 50 mg/m2 4-hour infusion). The dose-limiting toxicity using this novel schedule was hyperacute tumor lysis syndrome. Aggressive prophylaxis and exclusion of patients with leukocyte counts greater than 200x10(9)/L have made this drug safe to administer at the cohort 3 dose. Of the 42 patients treated, 19 (45%) achieved a partial response with a median response duration that exceeds 12 months. Responses were noted in patients with genetically high-risk disease, including 5 (42%) of 12 patients with del(17p13.1) and 13 (72%) of 18 patients with del(11q22.3). Flavopiridol administered using this novel schedule has significant clinical activity in refractory CLL. Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases. 相似文献
92.
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128 总被引:1,自引:0,他引:1
Gaffney DK Winter K Dicker AP Miller B Eifel PJ Ryu J Avizonis V Fromm M Small W Greven K 《International journal of radiation oncology, biology, physics》2007,69(1):111-117
PURPOSE: To determine the efficacy and patterns of initial failure for oral celecoxib, intravenous cisplatin, and 5-fluorouracil and concurrent pelvic radiotherapy in patients with locally advanced cancer of the cervix. METHODS AND MATERIALS: Patients were treated with concurrent 5-fluorouracil and cisplatin chemotherapy and pelvic radiotherapy and brachytherapy. Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy. The overall and disease-free survival rates were determined. RESULTS: A total of 84 patients were accrued, of whom 78 were eligible. The estimated 2-year disease-free survival and overall survival rate was 69% and 83%, respectively. Of the 78 patients, 24 had treatment failure: 3 with persistent local disease, 9 local only, 2 regional, 4 distant, 1 regional and distant, 1 local and distant, and 2 with local, regional, and distant disease, and 1 had died of cervical cancer without a reported site of first failure and 1 without evidence of disease. CONCLUSION: At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively. Recurrent disease developed in 24 patients, and, of those patients, 18 had a component of locoregional failure as a site of first failure. Thus, locoregional control continues to be problematic after chemoradiotherapy as delivered in our study. The identification of more active biologically targeted therapies is warranted for the treatment of advanced cancer of the cervix. 相似文献
93.
Tworoger SS Missmer SA Eliassen AH Barbieri RL Dowsett M Hankinson SE 《Cancer causes & control : CCC》2007,18(7):743-752
An association between physical activity and premenopausal breast cancer risk may be due, in part, to relationships with sex
hormones or growth factors. Therefore, we assessed whether MET-h/week of total physical activity (moderate-to-vigorous intensity),
walking, or vigorous physical activity, and h/week of standing or sitting were associated with plasma concentrations of several
hormones. We examined levels of estrogens, androgens, progesterone, prolactin, sex hormone binding globulin (SHBG), insulin-like
growth factor-1 (IGF-1), IGF binding protein-3, and growth hormone (GH) in 565 premenopausal women, ages 33–52 years, from
the Nurses’ Health Study II (NHSII). About 87% of women had both timed follicular and luteal samples; other women had one
untimed sample. In general we observed few associations between sex hormone or IGF levels and measures of physical activity
or inactivity. However, free testosterone was modestly inversely associated with total physical activity (p-trend = 0.02). Luteal estradiol, free estradiol, and estrone also were inversely associated with total physical activity
(p-trend = 0.10, 0.04, 0.01, respectively); however, the trend was substantially attenuated when excluding women with anovulatory
cycles or irregular cycles. These cross-sectional results suggest that physical activity and inactivity have limited associations
with premenopausal sex hormone and growth factor levels, except possibly luteal estrogens.
Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorized users.
Support for this project was from NIH grants CA67262, CA50385, P50 CA089393, and DAMD-17-02-1-0692. Dr. Eliassen was supported
by Cancer Education and Career Development Grant R25 CA 098566-2 from the National Cancer Institute. 相似文献
94.
Dowsett M Smith IE Ebbs SR Dixon JM Skene A A'Hern R Salter J Detre S Hills M Walsh G;IMPACT Trialists Group 《Journal of the National Cancer Institute》2007,99(2):167-170
Tumor expression of the proliferation antigen Ki67 is widely used to assess the prognosis of cancer patients. A change in the expression of Ki67 after short-term exposure of patients to therapeutic agents is frequently used as a pharmacodynamic marker of efficacy, particularly among breast cancer patients before undergoing surgery. To determine the clinical significance of the level of tumor cell proliferation during endocrine therapy for breast cancer, we measured the expression of Ki67 in tumor biopsy samples taken before and after 2 weeks of presurgical treatment with anastrozole or tamoxifen or the combination of anastrozole plus tamoxifen in 158 patients with hormone receptor-positive primary disease. In a multivariable analysis, we found that higher Ki67 expression after 2 weeks of endocrine therapy was statistically significantly associated with lower recurrence-free survival (P = .004) whereas higher Ki67 expression at baseline was not. Larger baseline tumor size and lower estrogen receptor level after 2 weeks of treatment were also statistically significantly associated with poorer recurrence-free survival (P < .001 and P = .04, respectively). Our data indicate that measurements of tumor Ki67 level after short-term endocrine treatment may improve the prediction of recurrence-free survival by integrating the prognostic value of Ki67 level at baseline with changes in Ki67 level that are associated with treatment benefit. 相似文献
95.
Bathen TF Jensen LR Sitter B Fjösne HE Halgunset J Axelson DE Gribbestad IS Lundgren S 《Breast cancer research and treatment》2007,106(2):181-189
The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning
magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary
lymphatic spread in breast cancer patients. Biopsies from breast cancer (n = 91) and adjacent non-involved tissue (n = 48) were excised from patients (n = 77) during surgery. HR MAS MR spectra of intact samples were acquired. Multivariate models relating spectral data to histological
grade, lymphatic spread, and hormone status were designed. The multivariate methods applied were variable reduction by principal
component analysis (PCA) or partial least-squares regression-uninformative variable elimination (PLS-UVE), and modelling by
PLS, probabilistic neural network (PNN), or cascade correlation neural network. In the end, model verification by prediction
of blind samples (n = 12) was performed. Validation of PNN training resulted in sensitivity and specificity ranging from 83 to 100% for all predictions.
Verification of models by blind sample testing showed that hormone status was well predicted by both PNN and PLS (11 of 12
correct), lymphatic spread was best predicted by PLS (8 of 12), whereas PLS-UVE PNN was the best approach for predicting grade
(9 of 12 correct). MR-determined metabolic phenotype may have a future role as a supplement for clinical decision-making-concerning
adjuvant treatment and the adaptation to more individualised treatment protocols. 相似文献
96.
Robert S. Tolhurst Ross S. Thomas Fiona J. Kyle Hetal Patel Manikandan Periyasamy Andrew Photiou Paul T. R. Thiruchelvam Chun-Fui Lai Marwa Al-sabbagh Rosemary A. Fisher Sayka Barry Tatjana Crnogorac-Jurcevic Lesley-Ann Martin Mitch Dowsett R. Charles Coombes Tahereh Kamalati Simak Ali Laki Buluwela 《Breast cancer research and treatment》2011,128(2):357-368
Estrogen receptor-?? (ER??) positive breast cancer frequently responds to inhibitors of ER?? activity, such as tamoxifen, and/or to aromatase inhibitors that block estrogen biosynthesis. However, many patients become resistant to these agents through mechanisms that remain unclear. Previous studies have shown that expression of ER?? in ER??-negative breast cancer cell lines frequently inhibits their growth. In order to determine the consequence of ER?? over-expression in ER??-positive breast cancer cells, we over-expressed ER?? in the MCF-7 breast cancer cell line using adenovirus gene transduction. ER?? over-expression led to ligand-independent expression of the estrogen-regulated genes pS2 and PR and growth in the absence of estrogen. Interestingly, prolonged culturing of these cells in estrogen-free conditions led to the outgrowth of cells capable of growth in cultures from ER?? transduced, but not in control cultures. From these cultures a line, MLET5, was established which remained ER??-positive, but grew in an estrogen-independent manner. Moreover, MLET5 cells were inhibited by anti-estrogens showing that ER?? remains important for their growth. Gene expression microarray analysis comparing MCF-7 cells with MLET5 highlighted apoptosis as a major functional grouping that is altered in MLET5 cells, such that cell survival would be favoured. This conclusion was further substantiated by the demonstration that MLET5 show resistance to etoposide-induced apoptosis. As the gene expression microarray analysis also shows that the apoptosis gene set differentially expressed in MLET5 is enriched for estrogen-regulated genes, our findings suggest that transient over-expression of ER?? could lead to increased cell survival and the development of estrogen-independent growth, thereby contributing to resistance to endocrine therapies in breast cancer patients. 相似文献
97.
Brand JS van der Schouw YT Dowsett M Folkerd E Luben RN Wareham NJ Khaw KT 《Maturitas》2012,71(3):274-278
Objective
Low-grade chronic inflammation is increasingly being implicated in cardiovascular disease (CVD) etiology and may represent an alternative pathway through which testosterone and sex hormone-binding globulin (SHBG) influence CVD risk. We examined the associations between endogenous testosterone, SHBG and total and differential white blood cell (WBC) counts in men.Methods
Cross-sectional study of 2418 men aged 40–78 years from the Norfolk population of European Prospective Investigation into Cancer (EPIC-Norfolk) who had no history of CVD or cancer and complete data on sex hormones (total testosterone (TT), SHBG and free testosterone (FT)) and WBC counts. Associations between sex hormones and WBC counts were assessed using linear regression models.Results
Higher SHBG and TT levels were associated with lower WBC counts. After adjustment for age, BMI, smoking, physical activity and diabetes status, total WBC count decreased by 0.163 (95% CI −0.236; −0.091) and 0.102 (−0.170; −0.034) per standard deviation (SD) increase in SHBG and TT respectively. Associations of SHBG and TT with total WBC count were mainly accounted for by a lower granulocyte count (β coefficient = −0.132 (−0.194; −0.070) per SD increase in SHBG and β coefficient = −0.104 (−0.161; −0.046) per SD increase in TT). No associations between FT and total and differential WBC counts were found.Conclusions
Endogenous TT and SHBG levels are inversely associated with total WBC and granulocyte count in middle-aged and older men. Even though the underlying mechanism and causal directionality requires further exploration, these results support a link between hormonal status and low-grade inflammation. 相似文献98.
99.
腹腔镜在小儿离断性肾盂成形术中的应用与随访 总被引:1,自引:0,他引:1
目的 探讨腹腔镜下离断性肾盂成形术的效果及适应证.方法 总结21例经腹腔途径行腹腔镜离断性肾盂成形术治疗肾盂输尿管连接部狭窄(UPJO)所致肾积水的经验,对比同期开放手术治疗的35例患儿术后影像学.结果 第一例腹腔镜肾盂成形术历时4 h 50 min,随后的20例为1 h 40 min~2 h 30 min,术中出血量5~10 ml.20例术后3~5 d出院,恢复好.1例术后7 d因患儿外伤性肾盂内出血,血块堵塞双J管,致肾盂漏尿、形成尿腹,遂行开放探查术;术中见吻合口良好,清除肾盂内血块,冲洗双J管,放置.肾造瘘管,7 d后拔除肾造瘘管出院.21例患儿术后4~6周拔除双J管.2组患儿均分别在术后1个月、3个月、6个月行B超或CTU检查.腔镜组吻合口通畅率为95.2%(20/21),开放组为100%(35/35),二者差异无显著性意义.结论 熟练掌握腹腔镜缝合技术,是圆满完成经腹腔镜离断性肾盂成形术的基础.腹腔镜下手术创伤轻微,手术效果与传统的开放手术无差别;在应用腹腔镜肾盂成形术的初期,宜选择中度以下肾盂扩张的病例,待熟练后,逐步应用于重度积水病例,确保手术效果. 相似文献
100.
目的:研究老年性痴呆(AD)和血管性痴呆(VD)患者睡眠障碍的特点及相关性。方法:对31例AD患者和30例VD患者采用阿森斯(Athens)失眠量表调查评分及临床资料比较分析。对研究对象进行筛选分组。从8个方面详细记录睡眠情况,按量表现规定进行评定。结果:AD患者和VD患者总体睡眠状况比较有显著性差异(t=2.251,P<0.05)。睡眠状况各因子比较,在总睡眠质量、白天情绪、白天思睡等3个方面无显著性差异(P>0.05)。在早醒、白天身体功能方面,两者有极显著差异(P<0.01)。在入睡时间、夜间苏醒、总睡眠时间等两者存在显著性差异(P<0.05)。结论:AD患者和VD患者都有睡眠障碍,AD患者在早醒、白天身体功能、夜间苏醒、总睡眠时间等方面都比VD患者差,而VD患者在入睡时间上比AD患者明显延迟。 相似文献